Eytan Breman
Mont, WAL, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells.
Journal: International journal of molecular sciences
Published: January 08, 2025
Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL.
Journal: Frontiers in immunology
Published: January 08, 2025
Engineering strategies to safely drive CAR T-cells into the future.
Journal: Frontiers in immunology
Published: April 02, 2024
Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?
Journal: Cells
Published: November 29, 2023
Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform.
Journal: Molecular therapy. Nucleic acids
Published: June 20, 2023
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: March 24, 2021
Overcoming Target Driven Fratricide for T Cell Therapy.
Journal: Frontiers in immunology
Published: August 08, 2018
Human plasmacytoid dendritic cells acquire phagocytic capacity by TLR9 ligation in the presence of soluble factors produced by renal epithelial cells.
Journal: Kidney international
Published: September 26, 2016
Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition.
Journal: Journal of immunology research
Published: January 31, 2016
HLA monomers as a tool to monitor indirect allorecognition.
Journal: Transplantation
Published: May 07, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026